Tenil http://www.tenil.net/ Wed, 21 Jul 2021 23:59:27 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://www.tenil.net/wp-content/uploads/2021/05/tenil-icon-150x150.png Tenil http://www.tenil.net/ 32 32 Updated controls make Texwrap’s TLS Series L-Sealers easy to program with 24/7 operation https://www.tenil.net/updated-controls-make-texwraps-tls-series-l-sealers-easy-to-program-with-24-7-operation/ https://www.tenil.net/updated-controls-make-texwraps-tls-series-l-sealers-easy-to-program-with-24-7-operation/#respond Wed, 21 Jul 2021 22:09:40 +0000 https://www.tenil.net/updated-controls-make-texwraps-tls-series-l-sealers-easy-to-program-with-24-7-operation/

WASHINGTON, Mo., July 16, 2021 – Texwrap’s TLS-series L-welders now come with improved Allen-Bradley controls and a standard HMI touchscreen interface, making them the ideal sealing machines for customers who want easy operation, one hand- reduced labor and maximum efficiency.

TLS L-Sealer Series Shrink Wrapping Systems are designed for customers who see increased business, but their existing packaging processes have limited automation. The TLS Series is an entry-level machine to help automate customers’ packaging capabilities by increasing throughput while reducing manpower within their production line. It was designed to be a workhorse for businesses as it can run continuously for three shifts a day, seven days a week.

The TLS series L-sealers simultaneously perform end and side sealing of a package, as well as front sealing of the back package. Sealing is achieved by introducing the product into the center ply film with cells photodetecting the leading and trailing edge of the product. The TLS Series L-welders feature Texwrap’s patented Motion Trim ™ technology. The benefit this technology brings to customers is that it increases throughput by running the infeed and outfeed conveyors at a speed of up to 100 feet per minute while the seal jaws are in motion, which makes it the fastest and most durable L-sealer on the market.

Applications well suited for the TLS Series L-Sealers include low to moderate product rates or where space is at a premium. It can wrap and seal a wide variety of products, magazines, food, drink, clothing, housewares… if something goes in a bag, the TLS series L-welders can probably handle it.

The design of the TLS series also includes fully automatic product indexing and horizontal or vertical electric eye package length adjustment to suit most package configurations, as well as a low profile film holder, a swiveling control panel and a touch screen recipe library.

The features and benefits of the TLS series L-welders include:

  • Clean wedge-cut tail removal: cleanly cuts the foil tail by squaring the package before sealing, resulting in consistently strong joints and superior aesthetics
  • Programmable multi-pack function: automatically assembles and packs single-lane multi-packs
  • Passage function: standard option to allow the product to move through the machine without wrapping the product in shrink film
  • Automatic reversing belt: the reversing function relaxes the film to create better seals and reduces film usage, especially with large size products
  • 10 years warranty

Technical performance specifications include:

  • Maximum Package Size: 10.5 “high x 19.5” wide x 32 “long
  • Minimum package size (with closing conveyor): 2 “long x 2.75” wide
  • Film width
  1. Maximum: 28 “folded in the center
  2. Minimum 6 “folded in the center
  3. Optional 64 “folded accessory with 32” unwinder
  • Conveyor speed: 20 to 100 feet per minute
  • Air requirements: 80 PSI, 4 CFM
  • Electrical requirements: 240 VAC, single phase (480 VAC optional)
  • Construction: standard heavy-duty welded tubular steel (corrosion resistant optional)
  • For more information on Texwrap’s TLS Series L-Welders, visit https://www.texwrap.com/ or dial 800-886-7421.


    About Texwrap

    Known as the industry innovator, Texwrap holds patents on some of the most important advanced technologies in the field of shrink wrapping and packaging. Texwrap produces automatic shrink wrapping systems, L-bar sealers, side sealers, tunnels, feeding solutions and conveyor systems for the food, bakery, food and beverage industries. industry, mail, pharmaceuticals, nutraceuticals, retail, printing and publishing. Texwrap also manufactures the Tekkra line of shrink wrap packaging systems. As part of the ProMach End of Line business line, Texwrap helps our packaging customers protect and develop the reputation and trust of their consumers. ProMach is performance, and the proof is in every package. Learn more about Texwrap on www.Texwrap.com.

    About ProMach

    ProMach is a family of premier packaging solutions brands serving manufacturers of all sizes and geographies in the food, beverage, pharmaceutical, personal care, and household and industrial products industries. . The ProMach brands operate across the entire packaging spectrum: filling and capping, flexible, pharmaceutical, product handling, labeling and coding, and end of line. ProMach also provides performance services including integrated solutions, design / build, engineering and productivity software to optimize packaging line design and deliver maximum uptime.

    ProMach designs, manufactures, integrates and supports the most sophisticated and advanced packaging solutions on the global market. Its diverse customer base, from Fortune 500 companies to the smallest private enterprises around the world, depends on reliable, flexible and technologically advanced equipment and integrated solutions. ProMach is headquartered near Cincinnati, Ohio, with manufacturing facilities and offices in the United States, Canada, Mexico, Brazil, Europe, United Arab Emirates, and China. For more information on ProMach, visit www.ProMachBuilt.com.

    Source link

    https://www.tenil.net/updated-controls-make-texwraps-tls-series-l-sealers-easy-to-program-with-24-7-operation/feed/ 0
    Spike from drug overdoses; Effective shock therapy; Psychiatrist indicted for “Pill-Mill” https://www.tenil.net/spike-from-drug-overdoses-effective-shock-therapy-psychiatrist-indicted-for-pill-mill/ https://www.tenil.net/spike-from-drug-overdoses-effective-shock-therapy-psychiatrist-indicted-for-pill-mill/#respond Wed, 21 Jul 2021 22:06:09 +0000 https://www.tenil.net/spike-from-drug-overdoses-effective-shock-therapy-psychiatrist-indicted-for-pill-mill/

    The American Psychiatric Association has issued a new call to action to combat the sharp rise in drug overdose death rates.

    Lyndra Therapeutics has been granted FDA clearance for the company’s proposed pivotal trial program, comprising a pharmacokinetic comparability study in 90 patients and a 6-month double-blind safety study for its investigational treatment of schizophrenia , risperidone (LYN-005).

    Even in high-income countries, about one in eight children under the age of 18 suffers from mental disorders, according to a multinational study of more than 60,000 children. (Evidence-informed mental health)

    Bone loss and cognitive decline go hand in hand, regardless of age in women. (Journal of Bone and Mineral Research)

    The American Academy of Sleep Medicine and the Sleep Research Society have released new evidence-based guidelines for recommended shift hours. “Rather than providing a single generic recommendation, these new guiding principles involve taking a more holistic view when defining personalized working hours for each workplace, taking into account not only physical fatigue, but also mental fatigue, time of day, work demands, safety risks, lifestyle and health factors, ”said co-author Indira Gurubhagavatula, MD, of the Perelman School of Medicine from the University of Pennsylvania in Philadelphia. (Journal of Clinical Sleep Medicine)

    Childhood lead exposure may play a role in shaping personalities in adulthood, altering traits such as pleasantness and neuroticism. (ScienceDaily)

    Electroconvulsive therapy was both safe and effective in reducing the risk of suicide in hospitalized patients with severe depression. (JAMA network open)

    A Colorado psychiatrist has been charged with his alleged role in running a “pill mill” – and is charged with prescribing a patient over 10,000 Adderall pills in just a few months. (CBS Denver)

    And in related news, a Massachusetts psychiatrist has been charged with healthcare fraud and illegal prescribing of controlled substances, including benzodiazepines and stimulants, without medical reason. (Hartford Daily Voice)

    Source link

    https://www.tenil.net/spike-from-drug-overdoses-effective-shock-therapy-psychiatrist-indicted-for-pill-mill/feed/ 0
    Decreased volumes at Coonoor tea auction due to adverse weather conditions https://www.tenil.net/decreased-volumes-at-coonoor-tea-auction-due-to-adverse-weather-conditions/ https://www.tenil.net/decreased-volumes-at-coonoor-tea-auction-due-to-adverse-weather-conditions/#respond Wed, 21 Jul 2021 10:48:36 +0000 https://www.tenil.net/decreased-volumes-at-coonoor-tea-auction-due-to-adverse-weather-conditions/

    For the sale of 29 of the Coonoor Tea Trade Association auctions which will be held on Thursday and Friday after Bakrid holidays in many countries, a volume of 23.84 lakh kg is offered.

    This is up to 1.20 lakh kg less than the bid for last week’s auction.

    The drop in supply is believed to be due to a drop in production due to unfavorable weather conditions. “The present times are not conducive to high-quality production of high-volume tea,” said Ramesh Chander, president of the Nilgiris Small Tea Growers’ Association. Activity area.

    “There has been a strong wind for the past ten days, which has made the tea leaves look like paper without the necessary juice. This will affect the quality of the tea made. In the absence of sun for a few days and the majority of small producers engaged in the local festival ‘Devahabba’ of the Baduga community last week, we expect a 20% drop in tea production until the end of August ” , did he declare.

    Of the 23.84 lakh kg offered for this week’s auction, up to 22.65 lakh kg belong to the CTC variety and only 1.19 lakh kg to the Orthodox variety. In the loose leaf tea counter, only 78,000 kg belong to the Orthodox while 17.41 lakh kg, CTC. Among the dust tea, only 41,000 kg belong to the Orthodox while 5.24 lakh kg, CTC. In total, 18.19 lakh kg belong to Leaf grades and 5.65 lakh kg belong to Dust grades.

    Pascoes Woodlands green tea, auctioned by Paramount Tea Marketing (SI) P Ltd, topped the auction last week when Shree Ganesh Tea Trading Company bought it for 305 kg. Among CTC teas, Homedale Estate’s Broken Orange Pekoe Fanning grade, auctioned by Global Tea Brokers, surpassed when Tea Services India Pvt Ltd bought it for 297 per kg.

    Quotes with brokers indicated 75-77 per kg for Plain Leaf grades and 156-198 for top grades. For ordinary dust grades, they ranged from 77 to 84 and for the best grades, from 174 to 216.

    Source link

    https://www.tenil.net/decreased-volumes-at-coonoor-tea-auction-due-to-adverse-weather-conditions/feed/ 0
    PACK EXPO Las Vegas is back https://www.tenil.net/pack-expo-las-vegas-is-back/ https://www.tenil.net/pack-expo-las-vegas-is-back/#respond Wed, 21 Jul 2021 10:16:22 +0000 https://www.tenil.net/pack-expo-las-vegas-is-back/

    As the grip of the COVID-19 pandemic loosens on society, in-person events are returning, including PACK EXPO Las Vegas, which takes place September 27-29 at the Las Vegas Convention Center. As of June 1, Las Vegas returned to pre-pandemic guidelines, but to ensure the safety of all attendees and exhibitors, efforts are being made, with updated health and safety protocols that meet regulations. government regulations and industry standards. PACK Ready– PMMI’s Commitment to Safety – provides a detailed list of protocols implemented by the Las Vegas Convention Center and show management.

    With over 1,500 exhibiting companies, PACK EXPO Las Vegas, co-located with Healthcare Packaging EXPO and produced by PMMI, the Association for Packaging and Processing Technologies, will welcome tens of thousands of people.

    Through booth demonstrations and free in-trade training, attendees will not only see the technology in action and have the opportunity to speak with suppliers, but they will also learn about industry best practices and advancements. For example, Domino Amjet, Inc. will showcase its pioneering beverage can coding solution. BluePrint Automation will demonstrate how its robotic case loader can eliminate track classification and potential jam points, thus increasing line efficiency. Additionally, Quadrel Labeling Systems will showcase its Distillery Double-Sided / Wrap-Around Labeling System, featuring a three-panel design for the needs of growing small businesses requiring rugged reliability at a modest price point.

    Seminars not to be missed

    Back on the three days of the show, free and educational 30-minute seminars on the innovation stage, showcasing cutting-edge technologies, best practices and case studies, presented by industry experts. Topics will include connecting your supply chain network to build resilience; the success of continuous improvement, based on the testimonials of 700 food, beverage and consumer packaged goods (CPG) manufacturers; and best practices of Industry 4.0 and digital transformation.

    The interactive forum will also return with 45-minute sessions, which begin with short presentations, moderated by subject matter experts and members of the OpX Leadership Network, on the latest industry trends, followed by panel discussions with peers on topics affecting many packaged goods companies. Keep an eye on the list of sessions which will be released soon.

    Bringing together the health sector

    A must is the Health Packaging EXPO located in the Lower South Hall of the Las Vegas Convention Center. Innovators from leading pharmaceutical companies will exhibit and attend the show. Some companies that recognize Healthcare Packaging EXPO as a leading trade fair for their pharmaceutical packaging and production needs are Amgen, Biogen, Fresenius Medical Care, Pfizer and Sanofi.

    Large-scale machinery will be on display with demonstrations throughout the hall as well as the latest advances and solutions in packaging and processing within the pharmaceutical industry. Exhibitors will offer a range of solutions for the pharmaceutical supply chain, including anti-counterfeiting, cleaning and sterilization, cold chain logistics, serialization / tracking and traceability and tamper-evident.

    Also in the living room

    The interactive PACK to the Future exhibit debuts this year, showcasing the past, present and future of the industry. It will feature selected items and machines from some of the world’s leading CPG and packaging companies. Industry experts, futurists, and business and financial leaders will talk daily about where the industry is now, where it is now and what the future holds for packaging and processing. Sessions will be divided into 30 minute increments on advancements, such as artificial intelligence, sustainability, etc.

    The reusable packaging phase, organized by the Reusable Packaging Association, will show how the implementation of a reusable packaging system can improve handling performance, reduce operating costs, create new economic values ​​and reduce costs. environmental impacts in the supply chain. The information will be conveyed in company presentations, product demonstrations, case study findings and industry panels.

    The Future Innovators Robotics Showcase will feature teams of high school students from the Las Vegas area demonstrating the creations they’ve designed and built, reflecting how the next generation workforce is driving innovation. Attendees and exhibitors are encouraged to see the robots built by these brilliant students, watch the demos, ask questions and talk with them about the field.

    A final not-to-be-missed event is the Cold Pressure Council Annual Conference (September 28-29), which will be held in conjunction with PACK EXPO Las Vegas and Healthcare Packaging EXPO, offering training on the latest high pressure processing technologies (HPP ) technologies. All attendees of this conference will receive free registration to PACK EXPO Las Vegas and Healthcare Packaging EXPO.

    Participants are encouraged to download the free PACK EXPO Las Vegas app to organize their schedules, so they can participate to the fullest. It includes all the functionality of My Show Planner on the PACK EXPO Las Vegas website at www.packexpolasvegas.com. The app allows users to create a personal itinerary for navigating the show by simply clicking on an exhibitor or session and adding it to their schedules, as well as their personal appointments. Attendees can use the app to search for exhibitors by name, keyword, vertical market, or category. They can also search for educational sessions by location or topic. In addition, the app includes interactive floor plans, exhibitor messages, event reminders, shuttle schedules, frequently asked questions, news, and notifications.

    The registration fee, which includes access to both PACK EXPO Las Vegas and Healthcare Packaging EXPO, is $ 30 until September 3, after which it drops to $ 130. For more information and to register online, visit packexpolasvegas.com.

    For those who cannot attend in person, PMMI now offers virtual aspects of the live event via EXPO Xpress PACK, where you can research products and innovations in digital showrooms and connect with solution providers during the event, wherever you are.

    Source link

    https://www.tenil.net/pack-expo-las-vegas-is-back/feed/ 0
    PrEP, the HIV prevention pill, must now be completely free in almost all insurance plans https://www.tenil.net/prep-the-hiv-prevention-pill-must-now-be-completely-free-in-almost-all-insurance-plans/ https://www.tenil.net/prep-the-hiv-prevention-pill-must-now-be-completely-free-in-almost-all-insurance-plans/#respond Tue, 20 Jul 2021 20:51:52 +0000 https://www.tenil.net/prep-the-hiv-prevention-pill-must-now-be-completely-free-in-almost-all-insurance-plans/

    In a move that should prove transformative for the national HIV prevention effort, the federal government has announced that almost all health insurers must cover the HIV prevention pill, known as PrEP, or pre-prophylaxis. -exposure, without cost sharing – including for the drug itself and, most importantly, for clinic visits and laboratory tests.

    This means that the entire experience of keeping a prescription for Truvada or Descovy, the two approved forms of PrEP, should now be completely free for almost everyone. A prescribing physician, however, must persuade an insurer that Descovy in particular is medically necessary for a specific patient to qualify for zero cost sharing for the use of that drug for HIV prevention.

    Guidelines that the Centers for Medicare and Medicaid Services, as well as the Department of Labor and the Department of the Treasury, sent to health insurers on Monday indicate that insurers have 60 days to comply with the mandate. The rule states that insurers should not charge a co-payment, coinsurance, or deductible for quarterly clinic visits and lab tests required to maintain a prescription for PrEP.

    Insurers were already required to stop billing reimbursable expenses for drugs by January 1, 2021.

    These additional requirements, which will remove what has likely been a substantial barrier to accessing PrEP for low-income people in particular, are the result of the US Preventive Services Task Force’s attribution to this form of prevention. HIV an “A” grade in 2019. Under the Affordable Care Act, such pricing for preventive health care services, including annual medical examinations or tests for various illnesses such as HIV itself , means that they must be covered by almost all insurers at no cost to the insured patient.

    HIV prevention advocates have hailed the new guideline as a change in the effort to promote PrEP among people at risk of HIV.

    “While we need state Medicaid authorities and insurance departments to monitor implementation, this memo from the federal government literally blew me away with joy,” said Jim Pickett, senior advocacy director for the. prevention and gay men’s health at AIDS Foundation Chicago. “This has the potential to remove many of the access barriers we face with providing PrEP. I look forward to dramatic improvements in access to PrEP, especially for communities most vulnerable to HIV.

    However, Carl Schmid, executive director of the HIV + Hepatitis Policy Institute, pointed out that many insurers are still not complying with the rule that they cannot charge consumers for their Truvada or Descovy prescriptions.

    Robert Greenwald, clinical professor of law at Harvard Law School, pledged to “work to enforce the new guidelines and ensure that the promise of this free preventive service to reduce HIV acquisition is fulfilled.”

    Truvada, which contains a pair of antiretroviral drugs also used to treat HIV, was approved for HIV prevention in 2012. Research indicates that when taken daily, the tablet reduces the risk of getting HIV by more than 99%. virus during sex with other men. percent. PrEP reduces the risk of HIV in women by at least 90 percent.

    After a slow start, PrEP began to gain popularity in 2014, as media attention on PrEP’s potential to turn the tide against the US epidemic increased. Descovy, which is associated with improvements in bone density and kidney function tests compared to Truvada, received the green light from the Food and Drug Administration in 2019.

    Both drugs are manufactured by Gilead Sciences, which is the dominant player in the HIV treatment market. As of this spring, Truvada has been available in generic form with a list price as low as $ 30 per month. In comparison, the two brand name drugs retail for a monthly price of about $ 1,800.

    In May, the Centers for Disease Control and Prevention released an estimate that in 2019, some 285,000 people were taking PrEP. This promising news has been tempered by the fact that PrEP use remains largely restricted to gay and bisexual white men.

    It is possible that the complete elimination of out-of-pocket costs for a PrEP prescription by insureds could improve PrEP use among black and Latino men who have sex with men in particular. Together, these demographics accounted for 46% of new HIV diagnoses in 2019, according to the CDC. Overall, about 70 percent of new HIV transmissions occur among gay and bisexual men.

    The CDC also released a new estimate in May that in the mid-2010s, the annual rate of new HIV transmissions in the United States remained constant for a few years before declining by about 8% between 2015 and 2019, to some 34,800 new cases.

    A recent article published in the Annals of Epidemiology by Aaron J. Siegler, associate professor at the Rollins School of Public Health at Emory University, and colleagues found that states that have expanded their Medicaid programs under the Act affordable care and those that offered programs to offset the costs of PrEP benefited from greater use of the prevention modality. In other words, if people can access PrEP for less or for free, they are more likely to take it.

    “Now, it’s important that those who are eligible for PrEP, as well as their providers, are aware of these new requirements,” Schmid said of the new guidelines for insurers on sharing the costs of PrEP. “We also need to hold insurers accountable for ensuring that they do their job by complying with their legal obligations. Plan reviews continue to show that many insurers are not in compliance, and we need state insurance regulators to enforce the law and the new guidelines. “

    As the future looks bright for access to PrEP for those with health insurance, a fiscal crisis awaits clinics offering this form of HIV prevention to the uninsured population, as reported. NBC News. Gilead easily provides free PrEP to low-income people who don’t have health insurance, but the drug company does not cover clinic visits and associated lab tests. And thanks to a crucial change in tax policy, the company has pledged from January 1, 2022, at least $ 100 million in funds that clinics that care for underserved populations have used to cover these costs. auxiliaries should drain their budgets.

    The leaders of these clinics expect access to PrEP for those without health insurance to shrink as a result, which could offset the improved access that their insured counterparts will now enjoy thanks to the news. federal guidelines.

    Kenyon Farrow, general manager of advocacy and organization at activist group PrEP4All, called on the federal government “to seek ways to cover uninsured people, especially in states without Medicaid expansion, so that they can access health care services. PrEP services ”.

    “If we are serious about ending the HIV epidemic,” said Farrow, “we need to ensure equal access to PrEP in all communities and not just for those who are insured.

    To pursue NBC output at Twitter, Facebook & Instagram

    Source link

    https://www.tenil.net/prep-the-hiv-prevention-pill-must-now-be-completely-free-in-almost-all-insurance-plans/feed/ 0
    Mindfulness meditation reduces depression in newly diagnosed MS patients: Lawson study – London https://www.tenil.net/mindfulness-meditation-reduces-depression-in-newly-diagnosed-ms-patients-lawson-study-london/ https://www.tenil.net/mindfulness-meditation-reduces-depression-in-newly-diagnosed-ms-patients-lawson-study-london/#respond Tue, 20 Jul 2021 19:00:33 +0000 https://www.tenil.net/mindfulness-meditation-reduces-depression-in-newly-diagnosed-ms-patients-lawson-study-london/

    Mindfulness meditation has shown promising results in treating depression in patients who have recently been diagnosed with multiple sclerosis, or MS, according to a study conducted by researchers at the Lawson Health Research Institute in London. .

    “Mindfulness brings people into the moment rather than worrying about what might happen in the future or thinking about what happened in the past,” said Dr Arlene MacDougall, psychiatrist and scientist to Lawson, in a statement.

    “It’s about centering yourself and gaining a sense of control over how you will react rather than reacting to what is going on inside or outside of you. “

    Read more:

    What mindfulness meditation can do for your health

    According to the study, the first results of which were published in May in the journal Multiple Sclerosis and Related Disorders, the researchers recruited 24 newly diagnosed patients with recurrent MS, or RMS, for the project.

    The story continues under the ad

    Half of the participants took part in ten mindfulness treatment sessions of the Mindfulness Without Borders program – while the other half served as a control group for the study, the researchers said.

    The study found that people in the mindfulness group reported better coping skills and less perceived stress, and their symptoms were reduced, said Dr. Sarah Morrow, neurologist and associate scientist at Lawson and director. from the London MS Clinic at LHSC.

    In particular, the study found promising results when it comes to treating depression in patients.

    “This can be a stressful time for people as they have just been diagnosed with a chronic neurological disease that will last the rest of their lives,” Morrow said in a statement.

    “They don’t know what’s going to happen next. Will they be deactivated? When is the next relapse? It can cause a lot of worry and stress, and we see a majority of MS patients suffering from mental health issues such as depression and anxiety. “

    Click to play the video:

    Mindfulness meditation: how it works and why it’s so popular

    Mindfulness Meditation: How It Works and Why It’s So Popular – February 6, 2020

    Multiple sclerosis has been described as a complex and unpredictable autoimmune disease, causing inflammation of the central nervous system, resulting in damage to myelin, the protective sheath that covers the nerves. The damage can lead to physical disability and cognitive impairment.

    The story continues under the ad

    Canada has one of the highest rates of MS in the world, according to the organization. On average, 12 people in Canada are diagnosed with MS every day, often between the ages of 20 and 49. Women are three times more likely to be affected.

    There is currently no cure for MS, but several treatments exist to manage it, and many more are in development. According to the MS Society, 17 disease-modifying therapies have been approved to date by Health Canada.

    Read more:

    Meditation, exercise are ways to cope with stress during COVID-19 return to normal

    “This pilot study demonstrates that a (mindfulness-based intervention) can improve short-term coping, depression and perceived stress in people newly diagnosed (within one year) with RMS”, indicates the conclusion of the study.

    The researchers say more research is needed to investigate measures to extend benefits beyond immediate intervention. According to Lawson, the research team is working to examine whether using mindfulness would help people in the more progressive stages of MS.

    Mindfulness meditation has grown into a multi-billion dollar industry, with hundreds of apps aimed at helping people achieve calm and relaxation. The most popular of these apps include Headspace and Calm, which each have millions of users.

    A 2018 study by the United States Centers for Disease Control and Prevention found that meditation was the fastest growing health trend among adults in the United States.

    The story continues under the ad

    – With files from Olivia Bowden

    © 2021 Global News, a division of Corus Entertainment Inc.

    Source link

    https://www.tenil.net/mindfulness-meditation-reduces-depression-in-newly-diagnosed-ms-patients-lawson-study-london/feed/ 0
    Active Pharmaceutical Ingredients Market Report https://www.tenil.net/active-pharmaceutical-ingredients-market-report/ https://www.tenil.net/active-pharmaceutical-ingredients-market-report/#respond Tue, 20 Jul 2021 15:03:28 +0000 https://www.tenil.net/active-pharmaceutical-ingredients-market-report/

    Visiongain has published a new report on Active Pharmaceutical Ingredients Market Report to 2031: API forecast (Branded / Innovative and Generic), by type of synthesis (Synthetic and Biotech), by application (diabetes, oncology, cardiovascular, central nervous system, analgesics and others) PLUS COVID-19 recovery scenarios.

    Impact of COVID-19 on the market for active pharmaceutical ingredients

    The COVID-19 pandemic has posed an unprecedented health risk. Small start-ups, biopharmaceuticals and pharmaceuticals have taken initiatives to develop treatments against target infections linked to Covid 19. Researchers have found a number of molecules capable of fighting the deadliest virus. Currently, around 155 molecules are in clinical research and around 45 molecules are in preclinical testing. To this end, several molecules have been reused such as Remdesivir, Lopinavir & Ritonavir, Chloroquine & Hydroxychloroquine, and Lopinavir with Ritonavir plus Interferon beta-1a. In March 2020, the World Health Organization (WHO) announced that the organization had started a global mega-trial of the four most promising drugs against SARS-CoV-2. Countries are in a global rivalry to develop and manufacture an effective treatment for SARS-CoV-2. It has led to an increase in funding and the search for therapeutic molecules that will lead to the demand for active pharmaceutical ingredients lately.

    Download an exclusive sample report @ https://www.visiongain.com/report/api-market/#download_sampe_div

    Market factors

    Growing prevalence of chronic disease
    The increasing incidence and prevalence of cardiovascular disease, osteoarthritis and multiple cancers is expected to be the major growth factors of the active pharmaceutical ingredients market during the forecast period. According to estimates from Cancer Australia, around 1,405 new cases of brain cancer are expected in 2017. In addition, according to the World Health Organization (WHO), the common cause of death is cardiovascular disease (CVD) in the world. In addition, according to the Centers for Disease Control and Prevention (CDC), nearly 1.70 million people die of chronic disease each year in the United States.

    Although chronic disease is the leading cause of death for both men and women, as women face unique health issues. About 37% of women suffer from chronic diseases, compared to 30% of men. In addition, according to estimates by the World Health Organization (WHO), by 2050, around 130 million people are expected to suffer from osteoarthritis worldwide. Thus, the increasing high prevalence of cardiovascular disease and other chronic disorders requires appropriate management of treatment to maximize patient outcomes. In turn, it is expected to achieve substantial levels growth of active pharmaceutical ingredients market within the allotted time.

    Availability of research funding
    Increasing research and development activities and funding from government and many public-private organizations in the development of new drugs ultimately contribute to the growth of the active pharmaceutical ingredients market. Growing government initiatives in emerging economies, the existence of a large number of pharmaceutical pipelines and their therapeutic applications are the crucial factors fueling the demand for active pharmaceutical ingredients, thus contributing to the growth of the target industry.

    Market opportunities

    Emerging market for biosimilars

    The increasing prevalence of acute and chronic diseases such as rheumatoid arthritis and blood disorders, the growing number of non-proprietary and non-patented biologic drugs, the positive results of ongoing clinical trials for biosimilars and the growing demand for biosimilars in various indications clinics are propelling the growth of the global biosimilars market.

    Biosimilars are a generic form of patented biologic drugs, so they do not need to meet the strict needs of many regulatory authorities, making them cost effective compared to patented biologics. The expiration of intellectual property rights of original organic products in the coming years is expected to create opportunities for the biosimilar market.

    Get the detailed table of contents @ https://www.visiongain.com/report/api-market/#download_sampe_div

    How the Active Pharmaceutical Ingredients Market Report Helps You
    In summary, our 500+ page report provides you with the following insights:

    • Revenue forecast to 2031 for Active pharmaceutical ingredients Market, with forecast for API, synthesis type, and application, each forecast globally and regionally – learn about the outlook for the industry, finding the most lucrative locations for investment and revenue
    • Revenue forecast to 2031 for 5 regional markets and 16 key national markets – See forecast for the active pharmaceutical ingredients market in North America, Europe, Asia-Pacific and the rest of the world. The market is also expected in the United States, Canada, Argentina, Brazil, Germany, France, United Kingdom, Italy, Spain, China, India, Japan and Australia among others. significant savings.
    • Outlook for established companies and those looking to enter the market, including company profiles of 10 of the leading companies involved in the active pharmaceutical ingredients market.

    Competitive landscape

    The main players operating in the Global Active Pharmaceutical Ingredients Market are AbbVie Inc., Mylan NV, Cipla Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Bristol-Myers Squibb Company, Aurobindo Pharma, Albemarle Corporation and Laboratories Dr Reddy’s Ltd.

    You will find quantitative and qualitative analyzes with independent predictions. You will receive information that only our report contains, staying informed thanks to this valuable business intelligence.

    To access the data contained in this document, please send an email contactus@visiongain.com

    Information found nowhere else
    With our survey, you are less likely to fall behind in your knowledge or miss an opportunity. See how you could benefit from your research, analysis and decisions. Also find out how you can save time and be recognized for your business knowledge.

    The Visiongain study is aimed at anyone needing business analysis for the Active pharmaceutical ingredients market and leading companies. Here you will find data, trends and forecasts. Please order our report now.

    Find more Visiongain research reports at Therapeutic drugs sector click on the following links:

    Do you have custom requirements that we can help you with? Do you need specific information about a specific country, geographic region, market segment or company? Contact us today, we can discuss your needs and see how we can help you: sara.peerun@visiongain.com

    About Visiongain

    Visiongain is one of the fastest growing and most innovative independent market information, the company publishes hundreds of market research reports which she adds each year to her vast portfolio. These reports provide in-depth analysis of 18 industries around the world. The reports cover a 10-year forecast, are hundreds of pages long, with in-depth market analysis and valuable competitive intelligence data. Visiongain works in a range of vertical markets, which can currently influence each other, these markets include the automotive, aviation, chemicals, cybersecurity, defense, energy, food and beverage, materials, packaging, pharmacy and utilities. Our customized and syndicated market research reports mean you can have tailor-made market information tailored to your business needs.


    Sara peerun
    Commercial director
    Visiongain Inc.
    Phone : + 44 207 549 9987
    United States Tel: 00 1 718 682 4567
    EU Tel: 00 353 1 695 0006
    E-mail: sara.peerun@visiongain.com
    The Web: https://www.visiongain.com/
    Follow us: LinkedIn | Twitter

    SOURCE Visiongain Limited.

    ]]> https://www.tenil.net/active-pharmaceutical-ingredients-market-report/feed/ 0 IPO Tatva Chintan subscribed 180 times https://www.tenil.net/ipo-tatva-chintan-subscribed-180-times/ https://www.tenil.net/ipo-tatva-chintan-subscribed-180-times/#respond Tue, 20 Jul 2021 14:04:19 +0000 https://www.tenil.net/ipo-tatva-chintan-subscribed-180-times/

    Tatva Chintan Pharma Chem’s IPO was subscribed 180.35 times. While the portion reserved for retail investors was subscribed 35.34 times, the quota for non-institutional investors received offers worth 512.22 times. The share of qualified institutional buyers received offers worth 185.23 times.

    The company had raised 150 crore from key investors prior to the issuance.

    The IPO consists of a new issue valued at 225 crore and an offer to sell shares valued at 275 crore by the promoter group. The price range for Tatva’s IPO was set at 1,073 to 1,083 per share.

    The IPO received offers for around 58.83 crore shares against 32.62 lakh shares on offer, according to data available from the ESB. Recall that the IPO was fully hedged within hours of opening Friday.

    Eight cos marks a hundred

    The IPO was the second most successful in 2021 in terms of oversubscription after MTAR Technologies, which saw its issue underwritten just over 200 times. Of the 27 companies that successfully entered the capital market this year, the public issues of eight companies have been underwritten more than 100 times.

    The Gujarat-based specialty chemicals manufacturing company exports most of its products to more than 25 countries including the United States, China, Germany, Japan, South Africa, and the United Kingdom .

    Proceeds from the new issue would be used to fund capital expenditures necessary for the expansion of the company’s Dahej manufacturing plant, the modernization of a research and development facility in Vadodara, and the overall objectives of the company. company, the company said in its draft prospectus.

    Source link

    https://www.tenil.net/ipo-tatva-chintan-subscribed-180-times/feed/ 0
    Braxia Scientific obtains approval for direct billing insurance on ketamine treatments for Veterans Affairs Canada customers https://www.tenil.net/braxia-scientific-obtains-approval-for-direct-billing-insurance-on-ketamine-treatments-for-veterans-affairs-canada-customers/ https://www.tenil.net/braxia-scientific-obtains-approval-for-direct-billing-insurance-on-ketamine-treatments-for-veterans-affairs-canada-customers/#respond Tue, 20 Jul 2021 11:31:00 +0000 https://www.tenil.net/braxia-scientific-obtains-approval-for-direct-billing-insurance-on-ketamine-treatments-for-veterans-affairs-canada-customers/

    TORONTO, July 20, 2021 / PRNewswire / – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for people with depression and related disorders, is pleased to announce that it has established direct billing practices with health insurance provider Medavie Blue Cross for eligible Canadian military veterans. The above development will allow 100% coverage of oral, nasal spray and intravenous ketamine treatments, plus travel costs, provided at the Canadian Center of Excellence for Rapid Treatment (CRTCE), a subsidiary in exclusive property of Braxia.

    This support from the Blue Cross will allow members of the Canadian Armed Forces and the Royal Canadian Mounted Police (RCMP), as well as their family members, to receive fully funded treatment without worrying about personal expenses.

    “We are grateful for this insurance coverage, which has made it easier for Canadian veterans to access this important treatment,” said Dr. Roger mcintyre, CEO of Braxia Scientific Corp., noting that clinics have already seen an increase in bookings. “Many veterans struggle with depression, PTSD and suicidal thoughts. Unfortunately, conventional treatments are often ineffective or only partially effective in people living with these conditions, leaving many suffering with persistent symptoms and a impairment of function. “

    The population of Canadian veterans is estimated at 629,300,1 while the RCMP employs nearly 30,200 people.2 Veterans Affairs Canada served more than 187,100 clients between 2019-2020.3 According to government statistics, almost 16% of full-time members of the Canadian Armed Forces experience depression at some point in their lives, while over 11% have reported symptoms of post-traumatic stress disorder (PTSD)4.

    The medical and scientific director of Braxia and the medical director of CRTCE, Dr. Josh Rosenblat, commented, “While we provide ketamine treatments for this population, we also carefully collect outcome data to help refine treatment protocols and quantitatively determine the true effectiveness of ketamine and related treatments in this population. We specifically monitor symptoms of depression, anxiety, suicidal tendencies and PTSD. We have seen promising benefits for many veterans who received this new treatment at our clinic and plan to release our results in the coming months. “

    Dr McIntyre added: “The presentation of depression in patients with PTSD and co-morbid trauma is often very different from that seen in the general population in that it is often more severe, chronic and not not sufficiently respond to conventional treatment approaches. In contrast, our experience at CRTCE, as well as published scientific literature, suggests that people with depression and a history of trauma and / or PTSD have a very reasonable chance of benefiting from ketamine treatment. “

    “A related, but different, priority is the reduction of suicide in the general population, particularly in populations at risk, which would include, but not be limited to, members of the Canadian Armed Forces and the RCMP. Current evidence indicates that ketamine is capable of rapidly and significantly reducing suicidal tendencies in people with depression and represents an important treatment route for people with suicidal thoughts and behaviors. “

    About Braxia Scientific Corp.

    Braxia Scientific is a medical research company with clinics providing innovative ketamine treatments for people with depression and related disorders. Through its medical solutions, Braxia aims to reduce the disease burden of brain-related mental disorders such as major depressive disorder, among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, treatment of mental health disorders, and (ii) research activities related to the discovery and commercialization of new drugs and delivery methods. . Braxia is developing ketamine and psilocybin derivatives and other psychedelics from its IP development platform. Through its wholly owned subsidiary, the Canadian Center of Excellence for Rapid Treatment Inc., Braxia currently operates multidisciplinary community clinics providing rapid onset treatments for depression located in Mississauga, Toronto, Ottawa, and Montreal.


    “Dr. Roger S. McIntyre
    Dr. Roger S. McIntyre

    Chairman and CEO

    The CSE has not reviewed and accepts no responsibility for the accuracy or relevance of this release.

    Caution regarding forward-looking information
    This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are “forward-looking statements”.

    Forward-looking statements include statements about the promise of ketamine-based treatments for depression and the potential of ketamine to treat other emerging psychiatric disorders, such as bipolar depression. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to differ materially from the future results, events or developments expressed or implied by such forward-looking statements. These risks and uncertainties include, among others, the inability of ketamine, psilocybin and other psychedelics to provide the expected health benefits and unintended side effects, dependence on obtaining and using maintenance of regulatory approvals, including the acquisition and renewal of federal, provincial, municipal, local or other approvals. licenses and engage in activities that may later be deemed illegal under national or international law. Psilocybin is currently a Schedule III controlled substance under the Controlled Drugs and Substances Act, SC 1996, c. 19 (the “CDSA”) and it is a criminal offense to possess such a substance under the CDSA without a statutory limitation or exemption. Health Canada has not approved psilocybin as a drug for any indication. These factors should be carefully considered and readers are cautioned not to place undue reliance on these forward-looking statements.

    Although the Company has attempted to identify material risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results differ from those anticipated, estimated or predicted. Additional information identifying the risks and uncertainties that could affect the financial results is contained in the documents filed by the Company with the Canadian securities regulators, including the amended and restated registration statement dated April 15, 2021, which are available at www.sedar.com. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements.

    SOURCE Braxia Scientific Corp.

    Related links


    Source link

    https://www.tenil.net/braxia-scientific-obtains-approval-for-direct-billing-insurance-on-ketamine-treatments-for-veterans-affairs-canada-customers/feed/ 0
    Alliance Pharma is doing well in the first half of the year https://www.tenil.net/alliance-pharma-is-doing-well-in-the-first-half-of-the-year/ https://www.tenil.net/alliance-pharma-is-doing-well-in-the-first-half-of-the-year/#respond Tue, 20 Jul 2021 08:45:58 +0000 https://www.tenil.net/alliance-pharma-is-doing-well-in-the-first-half-of-the-year/

    Healthcare company Alliance Pharma updated the market on its first half on Tuesday, saying it had traded “strongly”, with transparent earnings increasing 24% year-on-year to £ 80.9million, or 28% at constant exchange rates .

    The AIM-listed company said that with the exception of Amberen, which was acquired in December, transparent like-for-like revenue was £ 71.4million for the half-year ended. on June 30, or 9% more than in the first half of 2020, or 12% at constant exchange rates.

    Based on trading since the start of the year, its board said it expects underlying profit before tax for the entire year to be in line with market expectations.

    He said its consumer healthcare brands were performing well, with total division revenue up 30% to £ 56.8million, and comparable revenue, excluding Amberen, in up 8% to £ 47.3million.

    ‘Kelo-cote’ delivered another strong performance, with revenue up 54% to £ 21.9million, while Amberen continued to trade in line with its pre-acquisition expectations, generating revenue of £ 9.5 million, a steady increase in the currency of 10%. .

    Revenues for ‘Nizoral’ were 8% lower than the same period last year at £ 9.0 million, or 7% lower at constant exchange rates, mainly due to the phasing of orders from distributors.

    Alliance reported an increase in its prescription drug business during the period, with revenue increasing 12% to £ 24.1million, part of the negative impact of Covid-19 on the provision of treatment routine having subsided.

    Free cash flow for the period totaled £ 6.5million, up from £ 10.5million a year earlier, with the board attributing the reduction to the expected reversal of the fund’s favorable movements. turnover in the fourth quarter of 2020 and the sales schedule within the period.

    Net debt fell from £ 2.7m to £ 106.7m as of June 30, with group leverage reduced to 2.21x at the end of the period, from 2.43x at the end of December .

    Its directors said they still expected that number to drop below 2x by the end of the year.

    “Our consumer healthcare business continues to perform well – Kelo-cote in particular has had a very good first half,” said Peter Butterfield, Chairman and CEO.

    “We are pleased with Amberen’s performance in the first half of the year, and the brand’s integration into our US-based operations is now complete.

    “We expect the strong performance of the group to continue throughout the second half of the year, and anticipate that this will have a positive impact on cash generation and our ability to continue our deleveraging by the end of the year. “

    At 0909 BST, shares of Alliance Pharma were up 1.81% to 101.2p.

    Source link

    https://www.tenil.net/alliance-pharma-is-doing-well-in-the-first-half-of-the-year/feed/ 0